All In Biotech

Free tool

FAERS Monitor: Xocova

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220442 or its brand name (Xocova, Ensitrelvir). Reports on generic versions are filed under their own applications.

Reports

18

Serious

8

44% of reports

Hospitalization

6

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug interaction8
  • product use in unapproved indication7
  • drug half-life increased4
  • immunosuppressant drug level increased4
  • covid-193
  • covid-19 pneumonia3
  • drug clearance decreased3
  • blood creatinine increased2
  • drug ineffective for unapproved indication2
  • drug level increased2
  • off label use2
  • pneumonia2
  • accidental exposure to product1
  • anti-neutrophil cytoplasmic antibody positive vasculitis1
  • cytokine release syndrome1

Reports by year received

View as table
YearReports
20232
20248
20256
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,141 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug half-life increasedSignal442533.617567.4125,683
drug clearance decreasedSignal32691.0956.45,589
immunosuppressant drug level increasedSignal41416.9596.64,328
anti-neutrophil cytoplasmic antibody positive vasculitis1473.070.4117
covid-19 pneumoniaSignal3297.0105.7614
drug level increased2141.238.2156
drug interactionSignal858.935.2402
cytokine release syndrome158.38.714
drug ineffective for unapproved indication242.611.545
blood creatinine increased235.89.737
product use in unapproved indicationSignal733.018.5189
covid-19Signal320.07.137
accidental exposure to product111.31.72
pneumonia27.22.05
off label use22.70.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.